An 83-year-old man presented...consistent with a diagnosis of angiosarcoma....genomic profiling revealed amplification in VEGFR3, which plays a major role in lymphangiogenesis, a dual inhibitor of VEGFR2 and VEGFR3, pazopanib, was started in February 2013 at a dose of 400 mg daily, and was subsequently increased to 800 mg daily. The patient's right facial swelling was markedly reduced in 4 weeks (Figure 3), and high-resolution head and neck CT in April and June of 2013 further showed stable disease.